Ionis Pharmaceuticals, Inc.
IONS
$33.53
$1.273.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -41.91% | 69.32% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -41.91% | 69.32% | |||
| Cost of Revenue | -21.82% | 12.90% | |||
| Gross Profit | -178.36% | 73.86% | |||
| SG&A Expenses | -5.14% | 42.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.47% | 19.45% | |||
| Operating Income | -32.52% | 25.45% | |||
| Income Before Tax | -37.17% | 25.72% | |||
| Income Tax Expenses | 104.31% | 25.71% | |||
| Earnings from Continuing Operations | -40.81% | 25.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -40.81% | 25.72% | |||
| EBIT | -32.52% | 25.45% | |||
| EBITDA | -33.23% | 25.78% | |||
| EPS Basic | -40.17% | 30.15% | |||
| Normalized Basic EPS | -37.85% | 32.24% | |||
| EPS Diluted | -40.17% | 30.15% | |||
| Normalized Diluted EPS | -37.85% | 32.24% | |||
| Average Basic Shares Outstanding | 0.47% | 6.33% | |||
| Average Diluted Shares Outstanding | 0.47% | 6.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||